by The eosinophilic esophagitis market is estimated to be valued at US$ 245.92 Mn in 2023 and is expected to exhibit a CAGR of 33.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Eosinophilic esophagitis is a chronic inflammatory food antigen-mediated immune/allergic condition of the esophagus characterized by eosinophil-predominant inflammation. The disease causes esophageal dysfunction symptoms like dysphagia and food impaction. It requires long-term pharmacological treatment and dietary therapies for management.
Market Dynamics:
The eosinophilic esophagitis market is driven by increasing disease prevalence globally. According to studies, it has risen from 13 per 100,000 people in the US in 2002 to 71.2 per 100,000 people in 2017. The exact cause remains unknown but increasing environmental allergies, changes in dietary habits, and genome studies showing hereditary involvement are considered contributing factors for rising cases. Furthermore, growing awareness about the disease and increasing diagnosis rates fueled by endoscopic screening is boosting the market growth. While pharmacological therapies and topical corticosteroids provide symptomatic relief, there is no permanent cure available for EoE currently. This sizable patient pool needing long-term management creates significant market opportunities over the forecast period.
SWOT Analysis
Strength: Eosinophilic Esophagitis market has witnessed strong growth in the last few years owing to increasing prevalence of asthma, allergies and other immune disorders. The potential of targeted therapies and promising late stage pipeline provides growth opportunities. Growing awareness about the disease and its treatment options has boosted the market growth.
Weakness: High cost of targeted therapies hampers the market growth. Lack of approved drug and alternative treatment options poses challenge.
Opportunity: Rising geriatric population suffering from chronic disease propels the market growth. Growing healthcare expenditure in developing economies creates new opportunities.
Threats: Stringent regulatory approval process and clinical trial failure are major threats. Patent expiry of blockbuster drugs also impacts the market growth.
Key Takeaways
The Global Eosinophilic Esophagitis Market Share is expected to witness high growth, exhibiting CAGR of 33.3% over the forecast period, due to increasing prevalence of food allergies and asthma cases globally.
Regional analysis
North America dominates the global market owing to growing awareness, developed healthcare infrastructure and presence of key players. Asia Pacific exhibits fastest growth driven by vast patient pool, rising healthcare spending and improving medical facilities in emerging countries.
Key players
Key players operating in the Eosinophilic Esophagitis market are Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
